Question | Answer |
Lymphadenitis | inflammation of the lymph nodes |
Lymphangioma | tumor made of lymph vessel |
Lymphosarcoma | tumor arising from lymph tissue |
neuroblastoma | malignant tumor arising from immature nerve cells |
mononucleosis | condition of abnormally large number of monocuclear leukocytes in the blood |
mycobacteria | bacteria often associated with immuno-compromised persons |
sarcoma | tumor made from connective tissue, muscle or bone |
Splenomegaly | enlarged spleen |
Splenorrhagia | hemorrhaging from the spleen |
Toxoplasmosis | disease caused by protozoa sometimes related to ARC |
HIV | human immunodeficiency virus, virus that preceeds AIDS |
Immunodeficiency | a decrease of the immune response |
Immunosuppression | interference with the development of immune response |
leukopenia | abnormal decrease of white blood cells |
Macrophage | large monocytes that eat microorganisms |
lymphocyte | primary cell of the lymph system |
Malignant | tending to become progressively worse |
phagocyte | cells that eat or destroy other cells |
Metastasis | spread of disease from one location to another |
Remission | abatement or lessening in severity of syptoms of a disease |
Retrovirus | large group of viruses that reproduce during reverse transcription |
Syndrome | combination of symptoms that result from a single cause |
Virus | smallest microorganism causing infection |
Autoimmune | arising from and directed against an individual's own tissue |
Carcinoma | tumors that arise from epithelial tissue |
Chemotherapy | treatment with chemicals |
Dyscrasia | abnormal mix of cells |
ELISA | Enzyme Linked Immuno-Sorbant Assay, test for enzyme linked immunodeficiency |
AIDS | Acquired Immunodeficiency Syndrome |
leukemia | malignancy characterized by a progressive increase of abnormal leukocytes |
septicemia | blood poisoning |
antibody | proteins that defend the body against infection |
antigen | foreign substance which stimulates the production of antibodies |
lymph | clear fluid found in lymph vessels |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |